We are live on ! Find out more
CG

Carlyle Group Portfolio holdings

AUM $10.6B
1-Year Est. Return 11.25%
This Fund
S&P 500
This Quarter Est. Return
-11.02%
1 Year Est. Return
+11.25%
3 Year Est. Return
-0.47%
5 Year Est. Return
-4.92%
10 Year Est. Return
+7.54%
AUM
$1.59B
AUM Growth
-$493M
Cap. Flow
-$82.1M
Cap. Flow %
-5.17%
Top 10 Hldgs %
93.85%
Holding
33
New
8
Increased
4
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$54.9M
2
QTTB icon
Q32 Bio
QTTB
+$15.2M
3
DNUT icon
Krispy Kreme
DNUT
+$4.55M
4
JSPR icon
Jasper Therapeutics
JSPR
+$3.37M
5
SPWR icon
SunPower Inc
SPWR
+$2.42M

Top Sells

Rank Stock Value
1
GTM
ZoomInfo Technologies
GTM
+$146M
2
VERA icon
Vera Therapeutics
VERA
+$22.1M
3
GETY icon
Getty Images
GETY
+$841K
4
EFTR
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
+$12

Sector Composition

Rank Sector Weight
1 Healthcare 59.55%
2 Technology 28.63%
3 Consumer Staples 6.27%
4 Communication Services 2.41%
5 Real Estate 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NCNA
26
NuCana
NCNA
$5.45M
$845K 0.05%
667
– –
DASH icon
27
DoorDash
DASH
$80.2B
$572K 0.04%
+4,156
New +$490K
SYRE icon
28
Spyre Therapeutics
SYRE
$8.7B
$365K 0.02%
9,620
– –
AIU
29
DELISTED
Meta Data Limited American Depositary Shares, each representing ten (10) Class A Ordinary Shares
AIU
$241K 0.02%
62,880
– –
CFLT
30
DELISTED
Confluent
CFLT
$234K 0.01%
+7,683
New +$217K
XCUR icon
31
Exicure
XCUR
$10.7M
$161K 0.01%
56,327
– –
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
$28.7K ﹤0.01%
13,333
– –
VERA icon
33
Vera Therapeutics
VERA
$2.76B
– –
-1,438,155
Closed -$22.1M
1
2

Similar funds

SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $10.8B AUM 21.99% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $10.9B AUM 18.64% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

Carlyle Group's Q1 2024 Portfolio in Review

As of Q1 2024, Carlyle Group held 33 positions worth $1.59B, down 24% from $2.08B the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Carlyle Group withdrew a net $82.1M in Q1 2024, closing 1 position and reducing 3 holdings. Its most notable exit was Vera Therapeutics, an estimated $22.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 57% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Carlyle Group opened a new position in Q32 Bio worth $18.1M.

  • Carlyle Group's largest Q1 2024 buy was Q32 Bio: 1,102,741 shares worth $18.1M.
  • Carlyle Group added most to Soleno Therapeutics in Q1 2024, an estimated $54.9M increase.
  • Carlyle Group's biggest Q1 2024 reduction was ZoomInfo Technologies, cutting an estimated $146M.
  • Carlyle Group fully exited Vera Therapeutics in Q1 2024, selling an estimated $22.1M.
  • Carlyle Group's ten largest holdings make up 94% of its $1.59B portfolio in Q1 2024.
  • Carlyle Group opened 8 new positions and closed 1 in Q1 2024.
  • Carlyle Group's portfolio value fell 24% quarter-over-quarter to $1.59B.

Based on Carlyle Group's 13F filing for Q1 2024, filed 3 May 2024.